Medis initiated the design contest to encourage submission of designs for its Power Pack that are "aspirational, cool and sleek." The contest winner, Antonio Russomanno, submitted a design that was judged to exhibit these qualities. Mr. Russomanno's design can be viewed at the CTIA IT show at the Moscone Center in San Francisco from September 27th through September 29th at Medis' Booth #1103. He will be awarded a fully paid round trip for two to Medis' planned manufacturing facility in Ireland and will have the opportunity to see the manufacturing process for the Medis Fuel Cell Power Pack.

"In addition to its intrinsic design, what we liked about Mr. Russomanno's submission was that it demonstrated the breadth of possibilities for our Power Pack design," said Michelle Rush, Vice President of Marketing for Medis. "The winning design exhibits the particular qualities which we were seeking. It has a very sleek look and it reflects an approach that we believe most people will find innovative and attractive. While we are still also weighing designs submitted by our own professional designers for the final product design, Mr. Russomanno's design provides us with a high standard by which to judge all of the designs being submitted to us."

"This was a very exciting project for me," said Antonio Russomanno. "I really enjoyed designing a product that not only is a new emerging technology, but also a product that I, myself, as well as my wife and kids would use. I have 3 children who would use a Power Pack with their cell phones, electronic games and other devices, and their input into what is "cool" and what they would want to carry with them was important feedback for me throughout the design process. I look forward to getting the Power Pack product as it comes off the assembly line, particularly in a fun place like Ireland."

About Medis Technologies Ltd.

Medis Technologies' primary focus is on direct liquid fuel cell technology. Its business strategy is to sell its products to end users through retail outlets and service providers. Medis has also developed the CellScan with many potential applications relating to disease diagnostics and chemo sensitivity. Additionally, Medis' product pipeline includes other technologies, in varying stages of development.

This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risk and uncertainties, including, but not limited to, the successful completion of product development, the success of product tests, commercialization risks, availability of financing and results of financing efforts. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC.

This press release is available on Medis' web site at www.medistechnologies.com.